CORT
Corcept Therapeutics Continues to Thrive with Record-Breaking Revenue and Pivotal Phase III Study Results
Corcept Therapeutics, a leading biopharmaceutical company, has wrapped up an impressive year with record-breaking revenue and significant advancements in its proprietary selective cortisol modulator, relacorilant. According to the company's recent Q4 conference call transcript, Corcept's revenue for 2024 reached $675 million, marking a 40% increase from